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2-[4'-Methylsulfinyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (12a). 
Compound 4a (132 mg, 0.349 mmol) was dissolved in CH2Cl2 (15 mL). Then meta-
chloroperoxybenzoic acid (66.0 mg, 0.349 mmol, 77% dispersion in water) dissolved in CH2Cl2 (10 
mL) was added, and the reaction mixture was stirred for 5 min. The reaction mixture was diluted 
with CH2Cl2 (15 mL), washed with saturated aqueous sodium thiosulfate (15 mL) and saturated 
sodium hydrogen carbonate (15 mL), dried with MgSO4, filtered, and the solvent was evaporated in 
vacuo. Purification by dry column chromatography (SiO2, 12.6 cm2, 0 – 50% EtOAc / heptanes, 5% 
steps, 40 mL fractions. A little chloroform was needed to get the compound to dissolve and load the 
column) gave 12a (135 mg, 0.342 mmol, 98%) as a yellow solid. M.p. 132.0 - 135.0 °C. 1H NMR 
(500 MHz, CDCl3) δ 8.05 (d, J = 8.5 Hz, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 
7.73 (d, J = 8.6 Hz, 2H), 6.97 (s, 1H), 6.60 (dd, J = 11.3, 6.3 Hz, 1H), 6.51 (dd, J = 11.3, 6.1 Hz, 
1H), 6.40 (d, J = 6.0 Hz, 1H), 6.34 (ddd, J = 10.2, 6.1, 2.1 Hz, 1H), 5.85 (dd, J = 10.2, 3.8 Hz, 1H), 
3.83 (dt, J = 3.8, 2.1 Hz, 1H), 3.11 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 145.4, 140.5, 139.9, 
139.4, 138.6, 133.2, 131.4, 131.0, 130.9, 128.3, 128.3, 128.1, 127.9, 127.1, 121.7, 119.6, 115.2, 
112.8, 51.2, 45.3, 44.8 ppm. Elem. anal. calc. for C25H18N2OS·(CHCl3)0.60: C 66.06%, H 4.24%, N 
5.95%; found: C 66.26%, H 3.91%, N 5.70%. UV-vis (MeCN): λDHA (ε): 370 nm (26 x 103 M-1 cm-
1). λVHF (ε): 477 nm (26 x 103 M-1 cm-1). 
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2-[4'-Methylsulfonyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (13a). 
Compound 4a (126 mg, 0.333 mmol) was dissolved in CH2Cl2 (15 mL). Then meta-
chloroperoxybenzoic acid (126 mg, 0.732 mmol, 77% dispersion in water) dissolved in CH2Cl2 (10 
mL) was added, and the reaction mixture was stirred for 5 min. The reaction mixture was diluted 
with CH2Cl2 (15 mL), washed with saturated aqueous sodium thiosulfate (15 mL) and saturated 
sodium hydrogen carbonate (15 mL), dried with MgSO4, filtered, and the solvent was evaporated in 
vacuo. Purification by dry column vacuum chromatography (SiO2, 12.6 cm2, 0 – 100% EtOAc / 
heptanes, 10% steps, 40 mL fractions) gave the product 13a (143 mg, 0.326 mmol, 98%) as a 
yellow solid. Crystals suitable for X-ray crystallography were grown from CH2Cl2 / heptanes (The 
compound co-crystallized with CH2Cl2 (45%) according to both NMR, X-ray crystal structure 
analysis, and elemental analysis, even though the sample was left for 48 h under high vacuum). 
M.p. 178.3 - 179.3 °C (turned red at > 170 °C).  1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 8.6 Hz, 
2H), 7.77 (q, J = 8.6 Hz, 4H), 7.72 (d, J = 8.6 Hz, 2H), 6.96 (s, 1H), 6.59 (dd, J = 11.3, 6.2 Hz, 1H), 
6.50 (dd, J = 11.3, 6.2 Hz, 1H), 6.38 (d, J = 6.1 Hz, 1H), 6.33 (ddd, J = 10.2, 6.1, 2.1 Hz, 1H), 5.84 
(dd, J = 10.2, 3.8 Hz, 1H), 3.82 (dt, J = 3.8, 2.1 Hz, 1H), 2.79 (s, 3H) ppm. 13C NMR (125 MHz, 
CDCl3) δ 145.4, 142.9, 141.3, 139.6, 138.7, 132.8, 131.3, 131.1, 130.3, 128.2, 128.1, 127.9, 127.0, 
124.4, 121.5, 119.6, 115.3, 112.9, 51.2, 45.3, 44.2 ppm. Elem. anal. calc. for 
C25H18N2O2S·(CH2Cl2)0.45: C 68.12%, H 4.25%, N 6.24%; found: C 68.35%, H 4.32%, N 6.21%. 
UV-vis (MeCN): λDHA (ε): 369 nm (28 x 103 M-1 cm-1). λVHF (ε): 477 nm (28 x 103 M-1 cm-1). 
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2-(1,1'-Biphenyl-4-yl)-1,8a-dihydroazulene-1,1-dicarbonitrile (14a) and 2-(1,1'-Biphenyl-4-yl)-
azulene-1-carbonitrile (15). Compound 6a (253 mg, 0.662 mmol) was dissolved in toluene (30 
mL), and the solution was flushed with argon for 30 min. Water (20 mL) was added and the mixture 
was flushed with argon for an additional 30 min. Phenyl boronic acid (96.9 mg, 0.795 mmol), 
KF·2H2O (74.8 mg, 0.795 mmol), and Pd(PPh3)4 (38.3 mg, 0.033 mmol, 5 mol%) were added, and 
the reaction mixture was stirred for 48 h at 110 °C. The resulting purple reaction mixture was 
allowed to cool to rt and diluted with Et2O (200 mL). The solution was washed with sat. aqueous 
NH4Cl, dried with MgSO4, filtered, and concentrated under reduced pressure onto Celite. 
Purification by dry column vacuum chromatography (SiO2, 12.6 cm2, 0% - 77% toluene / heptanes, 
7% steps, 40 mL fractions) gave 14a (52.9 mg, 0.159 mmol, 24%) as a yellow powder and 15 (103 
mg, 0.337 mmol, 51%) as a purple solid. Product 14a: TLC (75% toluene / heptanes): Rf = 0.37. 
M.p. 176.2 - 178.6 °C. 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.5 Hz, 
2H), 7.63 (d, J = 7.1 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 6.93 (s, 1H), 6.58 
(dd, J = 11.3, 6.3 Hz, 1H), 6.49 (dd, J = 11.3, 6.1 Hz, 1H), 6.36 (d, J = 6.3 Hz, 1H), 6.32 (ddd, J = 
10.1, 6.1, 2.0 Hz, 1H), 5.85 (dd, J = 10.1, 3.8 Hz, 1H), 3.82 (dt, J = 3.8, 2.0 Hz, 1H) ppm. 13C NMR 
(125 MHz, CDCl3) δ 142.89, 140.02, 139.95, 138.91, 132.23, 131.08, 131.04, 129.43, 129.12, 
128.16, 127.98, 127.83, 127.19, 126.83, 121.08, 119.63, 115.34, 112.93, 51.29, 45.30. Elem. anal. 
calc. for C24H16N2 (332.40): C 86.72%, H 4.85%, N 8.43%; found: C 86.59%, H 4.52%, N 8.18%. 
MS (MALDI-): m/z = 332 [M-]. UV-vis (MeCN): λDHA (ε): 368 nm (21 x 103 M-1 cm-1). λVHF (ε): 
476 nm (23 x 103 M-1 cm-1). Product 15: M.p. 210.5 - 211.0 °C. 1H NMR (500 MHz, CDCl3) δ 8.66 
(d, J = 9.7 Hz, 1H), 8.43 (d, J = 9.7 Hz, 1H), 8.18 (d, J = 8.5 Hz, 2H), 7.83 – 7.75 (m, 1H), 7.78 (d, 
J = 8.5 Hz, 2H), 7.68 (dd, J = 8.3, 1.2 Hz, 2H), 7.61 (s, 1H), 7.56 (t, J = 9.7 Hz, 1H), 7.53 – 7.46 
(m, 3H), 7.40 (td, 8.3, 1.2 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3) δ 151.8, 146.0, 142.7, 142.4, 
140.5, 139.0, 138.0, 135.9, 133.4, 129.2, 129.1, 128.2, 128.0, 127.9, 127.3, 118.3, 116.6, 116.6, 
94.3 ppm. Elem. anal. calc. for C25H15N (305.37): C 90.46%, H 4.95%, N 4.59%; found: C 90.21%, 
H 4.73%, N 4.59%. MS (MALDI+): m/z = 412 [M+Ag+].  
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7-[4-(methylthio)phenyl]-1,8a-dihydroazulene-1,1-
dicarbonitrile (3a).  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
ppm
 
Figure 1. 1H-NMR spectrum of 3a in CDCl3 (500 MHz). 
 
Figure 2. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 3a in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7-[4-(methylthio)phenyl]-1,8a-dihydroazulene-1,1-
dicarbonitrile (3a). 
 
Figure 3. 13C-APT spectrum of 3a in CDCl3 (125 MHz). 
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Figure 4. UV-Vis spectra of DHA 3a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1  
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (4a). 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
ppm
 
Figure 5. 1H-NMR spectrum of 4a in CDCl3 (500 MHz). 
 
Figure 6. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 4a in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (4a). 
0102030405060708090100110120130140150
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Figure 7. 13C-APT spectrum of 4a in CDCl3 (125 MHz). 
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Figure 8. UV-Vis spectra of DHA 4a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
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2-(4'-Iodophenyl)-1,8a-dihydroazulene-1,1-dicarbonitrile (6a). 
 
Figure 9. 1H-NMR spectrum of 6a in CDCl3 (500 MHz). 
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Figure 10. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 6a in CDCl3 (500 / 125 MHz). 
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2-(4'-Iodophenyl)-1,8a-dihydroazulene-1,1-dicarbonitrile (6a). 
 
Figure 11. 13C-APT spectrum of 6a in CDCl3 (125 MHz). 
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Figure 12. UV-Vis spectra of DHA 6a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
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2-(4’-Iodophenyl)-7,8-dibromo-7,8,1,8a-tetrahydroazulene-1,1-dicarbonitrile (7). 
 
Figure 13. 1H-NMR spectrum of 7 in CDCl3 (500 MHz). 
 
Figure 14. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 7 in CDCl3 (500 / 125 MHz). 
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2-(4’-Iodophenyl)-7,8-dibromo-7,8,1,8a-tetrahydroazulene-1,1-dicarbonitrile (7). 
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Figure 15. 13C-APT spectrum of 7 in CDCl3 (125 MHz). 
Table 1. Assigned signals in 1H and 13C-NMR. *Not unambiguous. 
 1 2 3 3a 4 5 6 7 8 8a 
H - - 7.0 - 6.3 6.1 5.9 5.3 5.0 4.7 
C 44.5* 144.3 138.7 144.3 121.8 125.8 129.6 51.4 49.1 53.2 
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7-Bromo-2-(4’-iodophenyl)-1,8a-dihydroazulene-1,1-dicarbonitrile (8a).  
 
Figure 16. 1H-NMR spectrum of 8a in CDCl3 (500 MHz). 
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Figure 17. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 8a in CDCl3 (500 / 125 MHz).
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7-Bromo-2-(4’-iodophenyl)-1,8a-dihydroazulene-1,1-dicarbonitrile (8a). 
 
Figure 18. 13C-APT spectrum of 8a in CDCl3 (125 MHz). 
Table 2. Assigned signals in 1H and 13C-NMR. 
 1 2 3 3a 4 5 6 7 8 8a 
H - - 6.90 - 6.34 6.53 6.56 - 6.11 3.79 
C - - 132.1 - 120.7 132.3 133.3 - 120.3 51.1 
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Figure 19. UV-Vis spectra of DHA 8a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7-bromo-1,8a-dihydroazulene-1,1-dicarbonitrile (10a).  
 
Figure 20. 1H-NMR spectrum of 10a in CDCl3 (500 MHz). 
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Figure 21. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 10a in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7-bromo-1,8a-dihydroazulene-1,1-dicarbonitrile (10a). 
 
Figure 22. 13C-APT spectrum of 10a in CDCl3 (125 MHz). 
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Figure 23. UV-Vis spectra of DHA 10a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7,8-dibromo-1,7,8,8a-tetrahydroazulene-1,1-
dicarbonitrile (11). 
 
Figure 24. 1H-NMR spectrum of 11 in CDCl3 (500 MHz). 
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Figure 25. COSY (left) and 1H / 13C-APT HSQC (right) spectra of 11 in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylthio(1,1'-biphenyl)-4-yl]-7,8-dibromo-1,7,8,8a-tetrahydroazulene-1,1-
dicarbonitrile (11). 
 
Figure 26. 13C-APT spectrum of 11 in CDCl3 (125 MHz). 
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2-[4'-Methylsulfinyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (12a).  
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Figure 27. 1H-NMR spectrum of 12a in CDCl3 (500 MHz). 
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Figure 28. COSY (left) and 1H / 13C-APT (right) HSQC spectra of 12a in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylsulfinyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (12a). 
 
Figure 29. 13C-APT spectrum of 12a in CDCl3 (125 MHz). 
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Figure 30. UV-Vis spectra of DHA 12a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1  
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2-[4'-Methylsulfonyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (13a). 
 
Figure 31. 1H-NMR spectrum of 13a in CDCl3 (500 MHz). 
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Figure 32. COSY (left) and 1H / 13C-APT (right) HSQC spectra of 13a in CDCl3 (500 / 125 MHz). 
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2-[4'-Methylsulfonyl(1,1'-biphenyl)-4-yl]-1,8a-dihydroazulene-1,1-dicarbonitrile (13a).  
 
Figure 33. 13C-APT spectrum of 13a in CDCl3 (125 MHz). 
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Figure 34. UV-Vis spectra of DHA 13a and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
Table 3. Assigned signals in 1H and 13C-NMR. 
 1 2 3 3a 4 5 6 7 8 8a 
H - - 6.97 - 6.40 6.60 6.51 6.34 5.85 3.83 
C - - 133.4 - 121.7 131.0 131.4 127.9 119.6 51.2 
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2-(1,1'-Biphenyl-4-yl)-1,8a-dihydroazulene-1,1-dicarbonitrile (14a). 
 
Figure 35. 1H-NMR spectrum of 14a in CDCl3 (500 MHz). 
 
Figure 36. (left) COSY and (right) 1H / 13C-APT HSQC spectre of 14a in CDCl3 (500 / 125 MHz). 
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2-(1,1'-Biphenyl-4-yl)-1,8a-dihydroazulene-1,1-dicarbonitrile (14a). 
 
Figure 37. 13C-APT spectrum of 14a in CDCl3 (125 MHz). 
Table 4. Assigned signals in 1H and 13C-NMR. 
 1 2 3 3a 4 5 6 7 8 8a 
H - - 6.93 - 6.36 6.58 6.49 6.32 5.85 3.82 
C - - 132.2 - 121.1 131.1 131.0 127.2 119.6 51.3 
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Figure 38. UV-Vis spectra of DHA 14a  and its corresponding VHF measured in MeCN (left) and 
Arrhenius plot for VHF → DHA conversion (ln(k) vs. T-1) measured in MeCN (right). [k] = s-1 
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2-([1,1'-Biphenyl]-4-yl)-azulene-1-carbonitrile (15). 
 
Figure 39. 1H-NMR spectrum of 15 in CDCl3 (500 MHz). 
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Figure 40. (left) COSY and (right) 1H / 13C-APT HSQC spectre of 15 in CDCl3 (500 / 125 MHz). 
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2-([1,1'-Biphenyl]-4-yl)-azulene-1-carbonitrile (15). 
 
Figure 41. 13C-APT spectrum of 15 in CDCl3 (125 MHz). 
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Table 5. Measured rate constants (x 10-5 s-1) for the back-reaction (VHF → DHA), on which the 
Arrhenius plots are based.  
 70 °C 65 °C 60 °C 55 °C 50 °C 40 °C 30 °C 25 °C 
1b 681 ± 2 - 261 ± 0.9  95.0 ± 0.08 31.7 ± 0.05 - 5.31 ± 0.006 
6b 961 ± 3 - 375 ± 0.5  136 ± 0.08 45.4 ± 0.02 - 7.49 ± 0.002 
8b 237 ± 0.3 - 88.5 ± 0.04  30.4 ± 0.03 10.1 ± 0.02 - - 
4b 875 ± 3 - 342 ± 0.7  123 ± 0.3 41.2 ± 0.06 - 6.78 ± 0.003 
10b 192 ± 0.3 121 ± 0.05 73.0 ± 0.07  25.3 ± 0.02 - - 1.28 ± 0.5 
3b 706 ± 3* - 279 ± 1  101 ± 0.2 32.8 ± 0.2 9.81 ± 0.06 5.21 ± 0.002 
13b 906 ± 3*  358 ± 1 220 ± 0.2 130 ± 0.05 43.8 ± 0.02  7.32 ± 0.003 
12b   428 ± 0.4 263 ± 0.1 155 ± 0.04    
*Not included in the Arrhenius-equation. 
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Single-crystal X-ray diffraction 
Single-crystal X-ray diffraction data were collected at 150(2) K using graphite-monochromated 
MoKα radiation (λ = 0.7107 Å) on a Bruker-Nonius X8-APEXII CCD diffractometer. Data 
collection and processing were performed using the programs in the Bruker-Nonius suite Apex2 
(ver. 1.0–22). Data reduction and cell refinement were performed using SAINT (ver. 7.06a) and a 
multi-scan correction was applied using SADABS (ver. 2.10). The structures were solved using 
direct methods and refined by full-matrix least squares on all F2 data using Bruker SHELXTL (ver. 
6.10). 
 3a 10a 13a 
CCDC No- 857550 857551 857552 
Empirical formula C32H24N2S2·½CHCl3 C25H17BrN2S C25H18N2O2S·⅓CH2Cl2 
Formula weight 560.34 457.38 438.78 
Crystal system triclinic orthorhombic trigonal 
Space group P–1 P212121 P31c 
a (Å) 10.6179(7) 6.3853(4) 20.0736(12) 
b (Å) 11.4441(6) 10.4205(7) 20.0736(12) 
c (Å) 24.9964(13) 30.406(2) 9.1566(6) 
α (°) 81.750(2) 90 90 
β (°) 82.029(2) 90 90 
γ (°) 66.265(2) 90 120 
Volume (Å3) 2740.7(3) 2023.1(2) 3195.3(3) 
Z 4 4 6 
Calculated density (mg/m3) 1.358 1.502 1.368 
Absorption coeff. (mm-1) 0.366 2.149 0.261 
F(000) 1164 928 1368 
Crystal size (mm) 0.20 × 0.20 × 0.10 0.20 × 0.10 × 0.04 0.40 × 0.10 × 0.10 
Data collected 20974 19010 21616 
Unique data 9608 2919 3738 
Rint 0.047 0.052 0.052 
Observed data [I>2σ(I)] 6003 2606 3271 
R1 [I>2σ(I)] 0.068 0.074 0.059 
wR2 (all data)  0.194 0.149 0.167 
Goodness-of-fit (on F2) 1.04 1.15 1.07 
Diff. Density (e.Å-3) –0.89, 0.78 –0.69, 0.76 –0.50, 0.72 
Flack parameter  0.41(3) 0.06(11) 
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Compound 3a - CCDC 857550 
Compound 3a crystallized as a chloroform solvate, with one CHCl3 molecule and two molecules of 
3a in the crystallographic asymmetric unit. 
 
Compound 10a - CCDC 857551 
Crystals of compound 10a were plates, giving diffraction patterns with significant streaking along 
one direction, indicative of multiple plates. The diffracted intensity diminished relatively rapidly at 
higher angle, and the data were therefore truncated to 0.9 Å resolution. Full data were collected for 
two crystals from the same batch, and both showed the same disorder of the benzene ring. The 
disordered benzene ring is modelled in two orientations, with atoms C19 and C22 common to both 
orientations. C19 and C22 are split into two parts, but constrained to have identical coordinates and 
anisotropic displacement parameters. The major component (no suffix) of the other split atoms 
could be refined with anisotropic ADPs. The minor component (suffix A) is refined with isotropic 
ADPS. Both ring components were restrained to be flat, and the geometry of the minor component 
was restrained to be similar to that of the major component (using the FLAT and SAME 
instructions in SHELXL). The Me group of the SMe substituent does not appear to be disordered; 
its position is the same relative to the two orientations of the benzene ring. A short H···H contact is 
made from the Me group to the major component of the benzene ring: this reflects uncertainty in the 
position of the H atoms of the Me group. Refinement of the Flack parameter to 0.41(3) indicates 
racemic twinning, which was refined explicitly using TWIN and BASF instructions in SHELXL. 
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Compound 13a - CCDC 857552 
Compound 13a crystallizes in the trigonal space group P31c, with a solvent molecule located on the 
crystallographic 3-fold axis. The molecule resembles chloroform (with its local 3-fold axis aligned 
with the crystallographic 3-fold axis), but it must be dichloromethane since the crystals were grown 
from a dichloromethane/heptanes mixture. The single crystallographically independent Cl atom is 
therefore assigned a site occupancy factor of ⅔, and two H atoms are included with site occupancy 
factor ⅓. This corresponds to a DCM molecule disordered in three orientations around the 3-fold 
axis. In this case, the absolute structure could be determined acceptably by refinement of the Flack 
parameter. 
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An I(V) curve of the silver nanogap before deposition of DHA molecule 
 
Figure 42. An I(V) curve of the silver nanogap before DHA molecules were deposited. Presented is 
the average over 16 traces taken for negative-to-positive bias sweep direction and 16 re-traces taken 
for positive-to-negative bias sweep. An I(V) curve is featureless and the gap resistance is about 100 
GΩ,  which is 104 times higher then the resistance after the molecule was captured (see Fig. 8). The 
resistance of pristine gap was not sensitive neither to light nor to thermal cycling up to 25 K. 
